Skip to main content

Advertisement

Table 2 Serum NfL level correlations with demographic, clinical, cognitive, and biochemical measures

From: Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

  Whole sample rho(p value) CTRrho(p value) MCrho(p value) AMCrho(p value) SMCrho(p value)
N (N CSF) 60 (35) 18 (10) 42 (25) 20 (8) 22 (17)
Age 0.58 (< 0.001) 0.03 (0.92) 0.64 (< 0.001) 0.35 (0.13) 0.31 (0.16)
EYO 0.65 (< 0.001) −0.25 (0.31) 0.75 (< 0.001) 0.41 (0.07) 0.29 (0.19)
MMSE −0.65 (< 0.001) 0.24 (0.34) −0.77 (< 0.001) −0.30 (0.13) −0.48 (0.02)
CDR-SOB 0.62 (< 0.001) na 0.70 (< 0.001) na 0.35 (0.18)
CSF NfL 0.70 (< 0.001) 0.22 (0.58) 0.72 (< 0.001) 0.66 (0.16) 0.41 (0.17)
CSF Aβ1–42 −0.43 (0.01) 0.04 (0.91) −0.32 (0.12) 0.24 (0.57) 0.33 (0.19)
CSF total tau 0.59 (< 0.001) −0.68 (0.03) 0.71 (< 0.001) 0.19 (0.65) 0.39 (0.12)
CSF p-tau 0.60 (< 0.001) −0,56 (0.09) 0,71 (< 0.001) 0.19 (0.65) 0.41 (0.10)
  1. Significant results are indicated in bold typeface
  2. AMC asymptomatic mutation carriers, CTR non-carriers, CDR-SOB Clinical Dementia Rating sum of boxes, CSF cerebrospinal fluid, EYO estimated years from symptom onset, MC mutation carriers, MMSE Mini-Mental State Examination, na not applicable, NfL neurofilament light, p-tau phosphorylated tau, SMC symptomatic mutation carriers